10-Q: Corcept Therapeutics Q2 2026 Earnings Report

Corcept Therapeutics reports strong revenue growth driven by Hypercortisolism Products and Lifyorli, while navigating regulatory reviews and ongoing litigation.

Summary

• Corcept Therapeutics reported net income of $43.0 million ($0.40 basic EPS) for the three months ended June 30, 2026, and $11.2 million ($0.11 basic EPS) for the six months ended June 30, 2026.
• Total product revenue increased to $256.1 million for the three months and $421.1 million for the six months ended June 30, 2026, compared to $194.4 million and $351.6 million in the prior year periods.
• This growth was primarily driven by higher sales of Hypercortisolism Products and the commercial launch of Lifyorli in April 2026.
• Research and development expenses decreased slightly to $53.9 million for the quarter and $120.2 million for the six months, reflecting the advancement of development programs.
• Selling, general, and administrative expenses increased significantly to $156.9 million for the quarter and $302.3 million for the six months, due to increased commercialization efforts.
• The company ended the period with $111.0 million in cash and cash equivalents and $433.6 million in marketable securities.
• Corcept is awaiting an FDA decision on its relacorilant NDA, with a target date of December 17, 2026, and an EMA decision on Lifyorli in Q4 2026.
• The company is actively defending against multiple legal proceedings, including a securities class action and patent and antitrust litigation.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, with strong revenue growth and a solid liquidity position, but tempered by increased operating expenses, a prior regulatory setback for relacorilant, and ongoing legal challenges.

Positives

• Product revenue increased by 31.7% to $256.1 million for the three months ended June 30, 2026, compared to the same period in 2025.
• Product revenue increased by 19.8% to $421.1 million for the six months ended June 30, 2026, compared to the same period in 2025.
• Lifyorli, launched in April 2026, contributed $47.6 million in revenue for the second quarter.
• Hypercortisolism Products revenue increased to $208.6 million for the three months and $373.5 million for the six months, indicating continued demand.
• Net income for the three months ended June 30, 2026, was $43.0 million, a significant increase from $35.1 million in the prior year.
• Basic net income per common share was $0.40 for the three months ended June 30, 2026, up from $0.33 in the prior year.
• The company maintains a strong liquidity position with $111.0 million in cash and cash equivalents and $433.6 million in marketable securities as of June 30, 2026.
• Relacorilant's NDA resubmission to the FDA on June 17, 2026, with a target review date of December 17, 2026, represents progress towards potential approval.

Negatives

• Net income for the six months ended June 30, 2026, was $11.2 million, a substantial decrease from $55.7 million in the prior year.
• Basic net income per common share was $0.11 for the six months ended June 30, 2026, down from $0.53 in the prior year.
• Selling, general, and administrative expenses increased by 56.3% for the three months and 55.4% for the six months, impacting profitability.
• The FDA issued a Complete Response Letter (CRL) for relacorilant's initial NDA on December 30, 2025, requiring additional efficacy evidence.
• The company is involved in multiple significant legal proceedings, including a securities class action, patent litigation, and antitrust litigation, which could result in substantial costs and liabilities.
• The Inflation Reduction Act (IRA) is expected to limit revenue from Medicare patients and potentially reduce profits.
• The company faces ongoing patent litigation regarding Korlym, with a recent appellate court affirming a non-infringement ruling.
• The company's reliance on third-party vendors for manufacturing and distribution introduces operational risks.

Risks

• Failure to generate sufficient revenue from the sale of Korlym, its authorized generic, and Lifyorli could harm financial results and stock price.
• The availability and adoption of generic versions of Korlym, other than its authorized generic, could adversely affect business and financial position.
• Public perception of mifepristone or legislation limiting its distribution or use for pregnancy termination may limit the ability to sell Hypercortisolism Products.
• New laws, government regulations, or changes to existing laws and regulations could make it difficult or impossible to obtain acceptable prices or adequate insurance coverage and reimbursement for Products.
• The company's efforts to discover, develop, and commercialize product candidates may not succeed, as clinical drug development is lengthy, expensive, and often unsuccessful.
• Failure to obtain or maintain regulatory approvals for product candidates would prevent their commercialization.
• Litigation is slow, expensive, and uncertain, and the company may not be able to secure, maintain, or effectively assert patent protection for its products.
• The company is subject to ongoing legal proceedings, including a securities class action, patent litigation, and antitrust litigation, which could result in substantial costs and liabilities.

Future Outlook

Corcept expects its selling, general, and administrative expenses to be higher in 2026 than in 2025 due to increased commercial and administrative activities. Research and development expenses are also expected to be higher in 2026 than in 2025 as clinical programs advance and new trials are initiated. The company anticipates funding operations and planned R&D activities over the next 12 months and beyond without needing to raise additional funds, though they may choose to do so for other reasons. The Inflation Reduction Act is expected to limit revenue from Medicare patients and may materially reduce profits in 2026 and beyond.

Management Comments

• "We are committed to developing and commercializing medications that treat severe and life-threatening disorders by modulating the effects of the hormone cortisol."
• "Our strong revenue growth reflects the increasing adoption of our products and our ongoing commitment to patient access."
• "We continue to advance our pipeline of selective cortisol modulators, with promising developments in oncology, metabolic diseases, and neurologic disorders."
• "We are actively engaged in defending our intellectual property and navigating the complex legal and regulatory landscape."

Industry Context

StockSavvy.ai notes that Corcept Therapeutics operates in the highly competitive biopharmaceutical sector, focusing on niche therapeutic areas like endocrinology and oncology. The company's success hinges on the efficacy and market adoption of its specialized drugs, particularly Korlym and the newly launched Lifyorli. The increasing scrutiny on drug pricing and regulatory pathways, as highlighted by the Inflation Reduction Act and ongoing litigation, presents significant challenges and opportunities within this industry.

Comparison to Industry Standards

• Corcept's revenue growth of 31.7% for the quarter is strong compared to the average revenue growth of many mid-cap pharmaceutical companies, which often hover in the single to low double digits.
• The significant increase in SG&A expenses is typical for a company launching a new product (Lifyorli) and expanding commercial efforts, aligning with industry practices for market penetration.
• The R&D spend as a percentage of revenue has decreased, which can be a positive sign of pipeline maturation or a concern if it indicates reduced investment in future growth. Industry benchmarks vary widely, but a sustained R&D spend of 15-25% of revenue is common for growth-oriented biopharma companies.
• The company's cash and marketable securities position of over $544 million provides a substantial buffer, which is generally considered healthy for a company of its size and stage, allowing for continued investment and operational flexibility.

Legal Proceedings

• Purported Securities Class Action filed February 20, 2026, alleging misleading statements regarding relacorilant NDA.
• Teva Patent Litigation regarding Korlym generic version; appellate court affirmed non-infringement ruling on February 19, 2026.
• Antitrust Litigation filed by Teva in June 2024, alleging antitrust and unfair business practices; trial scheduled for March 2027.
• Aetna Litigation filed February 2025, with allegations similar to Teva Antitrust Litigation; remanded to state court.
• Qui Tam Litigation filed in 2017 by a former employee; DOJ declined to intervene, but relator is pursuing the action.
• Shareholder derivative complaint filed April 10, 2026, naming executive officers and directors, based on statements in the Securities Action.

Stakeholder Impact

• Shareholders: Potential for stock price volatility due to litigation, regulatory decisions, and financial performance. Strong revenue growth is a positive, but increased expenses and prior regulatory setbacks are concerns.
• Employees: Continued investment in R&D and commercialization may lead to growth opportunities, but increased SG&A could impact profitability. Stock-based compensation is a significant expense.
• Customers (Patients): Continued access to Hypercortisolism Products and Lifyorli is supported by patient assistance programs and specialty pharmacy distribution. Potential impact from IRA on Medicare coverage.
• Suppliers: Reliance on third-party vendors for API and manufacturing introduces supply chain risks.
• Creditors: The company's strong cash position and lack of debt suggest low immediate risk to creditors.

Next Steps

• Awaiting FDA decision on relacorilant NDA with a target date of December 17, 2026.
• Awaiting EMA decision on Lifyorli MAA, expected in Q4 2026.
• Continuing to defend against legal proceedings, including the securities class action, Teva patent litigation, antitrust litigation, and qui tam litigation.
• Monitoring the impact of the Inflation Reduction Act on future revenue and profits.
• Advancing other development programs in oncology, metabolic diseases, and neurologic disorders.

Key Dates

Recommendation

The company demonstrates strong revenue growth and a healthy cash position, driven by its core products. However, significant increases in operating expenses, ongoing complex litigation, and the uncertainty surrounding the relacorilant NDA resubmission and the impact of the Inflation Reduction Act warrant a cautious approach. While the launch of Lifyorli is positive, the overall risk profile suggests holding the stock until regulatory and legal uncertainties are resolved.

Keywords

Corcept Therapeutics, Form 10-Q, Quarterly Report, Korlym, Lifyorli, Relacorilant, Hypercortisolism, Ovarian Cancer